RxDoctor Payments Data

Catherine McDermott, APRN

Psychiatric/Mental Health · Bradenton, FLNPI 1609838119

Payments from drug & device makers

$8,302in general payments, 2019–2025

Across 78 payments — averaging $106.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$6K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$822
  • Acadia Pharmaceuticals Inc$682
  • Lundbeck LLC$642
  • MDD US Operations, LLC$107
  • Neurocrine Biosciences, Inc.$51
  • plus $44 from 3 others

What the payments were for

  • Consulting fees$2,27827%
  • Speaking & faculty fees$3,76645%
  • Travel & lodging$80910%
  • Food & beverage$1,44917%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,302 in reported general payments places this provider in the 95th percentile of 3,096 psychiatric/mental health providers in Florida.

See all psychiatric/mental health providers in Florida

Medicare billing

Part B allowed, 2024
$245,819
Medicare patients
296
Services billed
2,448

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate11$95,117
RexultiBrexpiprazole31$44,320
Quetiapine Fumarate1,116$20,247
Mirtazapine585$11,503
Divalproex Sodium219$8,156
Memantine Hcl167$6,951
Donepezil Hcl323$6,029
Sertraline Hcl547$6,024
Aripiprazole104$4,745
Escitalopram Oxalate319$4,646
Trazodone Hcl345$4,174
Desvenlafaxine Succinate ErDesvenlafaxine Succinate62$3,872
Duloxetine Hcl95$3,055
Olanzapine103$2,348
Bupropion XlBupropion Hcl77$2,238

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$51$95,11711 claims
Otsuka America Pharmaceutical, Inc.Rexulti$5,954$44,32031 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,096 psychiatric/mental health providers in Florida.

Other psychiatric/mental health in Bradenton

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →